Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidodiphosphate SCHEMBL125276 | 0.86 | — | — | |
| Imidodiphosphate SCHEMBL10787965 | 0.82 | CA2 (0.36) | CA2SLC34A1MMP2KDM4ETHRB | |
| Imidodiphosphate SCHEMBL27630294 | 0.82 | CA2 (0.36) | CA2SLC34A1MMP2KDM4ETHRB | |
| Imidodiphosphate SCHEMBL29225723 | 0.82 | CA2 (0.36) | CA2SLC34A1MMP2KDM4ETHRB | |
| Imidodiphosphate SCHEMBL28152486 | 0.82 | CA2 (0.36) | CA2SLC34A1MMP2KDM4ETHRB | |
| Imidodiphosphate SCHEMBL11583948 | 0.78 | CA2 (0.33) | CA2SLC34A1 | |
| Imidodiphosphate SCHEMBL10940911 | 0.75 | CA2 (0.40) | CA2MMP2MMP3MMP8 | |
| SCHEMBL3074407 | 0.72 | — | — | |
| SCHEMBL16383140 | 0.72 | — | — | |
| SCHEMBL28687626 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452489-B1 | CATALYST COMPOSITION FOR OLIGOMERIZATION REACTION | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2025-07-23 | — | — | EP | claimed |
| US-20250050317-A1 | CATALYST COMPOSITION FOR OLIGOMERIZATION REACTION | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2025-02-13 | — | — | US | claimed |
| EP-4452489-A1 | CATALYST COMPOSITION FOR OLIGOMERIZATION REACTION | SABIC Global Technologies B.V. (NL) | 2024-10-30 | — | — | EP | claimed |
| CN-118804799-A | For oligomerization reactions catalyst composition | SABIC环球技术有限责任公司 | 2024-10-18 | — | — | CN | claimed |
| US-12105259-B2 | Compact folded lenses with large apertures | COREPHOTONICS LTD. (IL) | 2024-10-01 | — | — | US | claimed |
| EP-3465313-B1 | COMPACT FOLDED LENSES WITH LARGE APERTURES | COREPHOTONICS LTD (IL) | 2023-08-30 | — | — | EP | claimed |
| WO-2023118226-A1 | CATALYST COMPOSITION FOR OLIGOMERIZATION REACTION | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2023-06-29 | — | — | WO | claimed |
| CN-116127582-A | Method for setting height of upper and lower layers of two-stage step-free reinforced soil structure | 合肥工业大学 | 2023-05-16 | — | — | CN | claimed |
| CN-114447116-A | Semiconductor structure | 新唐科技股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20260032994-A1 | Multilevel converter system | PULSETRAIN GmbH (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20260029623-A1 | FOLDED CAMERA LENS DESIGNS | COREPHOTONICS LTD (IL) | 2026-01-29 | — | — | US | disclosed |
| EP-4148477-B1 | IMAGING LENS SYSTEM | APPLE INC (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4452489-B1 | CATALYST COMPOSITION FOR OLIGOMERIZATION REACTION | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2025-07-23 | — | — | EP | disclosed |
| CN-118538821-B | Optical device and imaging system | 奥特逻科公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20050130270-A1 | Use of nucleoside derivatives comprising a citrate group for the production of antibodies having an affinity for triphosphorylated nucleosides | Centre National de la Recherche Scientifique- CNRS, an organization of France (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1495325-A1 | USE OF NUCLOEOSIDE DERIVATIVES COMPRISING A CITRATE GROUP FOR PRODUCING ANTIBODIES HAVING AFFINITY FOR TRIPHOSPHORYLATED NUCLEOSIDES AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-01-12 | — | — | EP | disclosed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003075009-A1 | USE OF NUCLOEOSIDE DERIVATIVES COMPRISING A CITRATE GROUP FOR PRODUCING ANTIBODIES HAVING AFFINITY FOR TRIPHOSPHORYLATED NUCLEOSIDES AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260032994-A1 | Multilevel converter system | PC, MPC2, HCN3 | CA2 1901/4885SLC34A1 486/4885MMP2 3905/4885 |
| US-20260029623-A1 | FOLDED CAMERA LENS DESIGNS | FMNL1, NCS1, CFL1 | CA2 392/4885SLC34A1 3228/4885MMP2 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.